Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …

Introduction Nivolumab has demonstrated efficacy against metastatic non-small cell lung
cancer (NSCLC). However, immune-related adverse events can occur, among which …

Highlights•Administering nivolumab may challenge NSCLC patients with IIP.•We performed
a multicenter phase-II trial to assess nivolumab's efficacy and safety.•The 6 months PFS rate …

Objectives The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer
(NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear. Materials and …

Background/Aim: Nivolumab has a promising efficacy for patients with non-small-cell lung
cancer (NSCLC) as second-line or later treatment, and after radiotherapy as abscopal effect …

Introduction Nivolumab has been shown to be effective and safe in previously treated
patients with advanced non-small cell lung cancer (NSCLC). However, little is known …

Objectives Drug-induced interstitial lung disease (ILD) is often associated with high
mortality; however it is difficult to predict and manage. we examined the clinical findings and …

Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is
a potentially life‐threatening adverse event. The purpose of this study was to evaluate …

Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …

Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non–small-cell lung cancer based on the results from phase III …